Presurgical targeted therapy delays relapse of high-risk stage 3 melanoma
A pair of targeted therapies given before and after surgery for melanoma produced at least a six-fold increase in time to progression compared to standard-of-care surgery for patients with stage 3 disease, researchers at The University of Texas MD Anderson Cancer Center report in Lancet Oncology. Patients who had no sign of disease at surgery after combination treatment did not progress to metastasis.
Early results of the study...
National Academy of Sciences awards Kovalenko medal to immunotherapy pioneer Allison
Cancer immunotherapy innovator Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive...
MD Anderson and UT Health San Antonio applaud San Antonio City Council for increasing tobacco sale age to 21
The University of Texas MD Anderson Cancer Center and UT Health San Antonio applaud the actions of the San Antonio City Council today in voting...
MD Anderson experts to share latest in cancer treatment, research
Leaders of The University of Texas MD Anderson Cancer Center will head to Palm Beach Jan. 22 to present innovations in cancer research, treatment and prevention. The Making Cancer History® seminar will be held 9-11 a.m. at The Colony Hotel, 155 Hammon Ave. Doors open at 8:30 a.m. with a breakfast buffet.
The seminar is open to the public. Guests will have the opportunity to meet MD Anderson’s new president; learn about the latest...
New cancer model shows genomic link between early-stage and invasive breast cancer types
A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to...